TechNet-21 - Forum

This forum provides a place for members to ask questions, share experiences, coordinate activities, and discuss recent developments in immunization.
  1. Dr Khalid
  2. Service delivery
  3. Monday, 13 May 2019
  4.  Subscribe via email

Dear all

I encountered operational challege were during SIA, specifically OBR using mOPV2 antigen. I observed that the fixed post team were given only bOPV which is the right antigen for routine while ignoring the purpose of the campaign (mOPV2 not given). They were intructed to give both mOPV2 and bOPV concurrently in other to ensure children received RI and SIA doses. When we reffered to the stakeholders it was revealed that guideline stipulated that, child should receive only mOPV2 and resheduled for bOPV next contact. i have little imformation that needs clarification from immunzation experts and/or refference materials for capacity building in support of the guideline.

1. What is the possible consequence of given mOPV2 and bOPV at same time? any scientific justification.

2. Weighing the risk of missed oppurtunities and combining both antigens at same, which one should i prioritised?

Thanks alot waiting for your input.

Dr Khalid Accepted Answer
0
Votes
Undo

Dear sir, agree with your points. does that mean given them at same time is a risk? What exactly should be the reason behind suspending bOPV. As innovation we used fixed post immunization team in area with lower RI performance.

Thanks

  1. one week ago
  2. Service delivery
  3. # 1
Dr A S Bose Accepted Answer
0
Votes
Undo

Quite an amusing conundrum. Using mOPV2 and bOPV together similar to using tOPV.

During an SIA round we don't usually give routine doses. Not much harm done if you do but it's operationally confusing.   

  1. one week ago
  2. Service delivery
  3. # 2


There are no replies made for this post yet.
However, you are not allowed to reply to this post.